课题基金 / 基金详情

Association of electroconvulsive therapy with health outcomes in older adults with co-occurring depression and dementia

Association of electroconvulsive therapy with health outcomes in older adults with co-occurring depression and dementia
电休克治疗与同时患有抑郁症和痴呆症的老年人健康结果的关系
批准号:
10119074
负责人:
SAMUEL WILKINSON
金额:
$22.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-05 至 2021-01-31

项目摘要

项目成果

SAMUEL WILKINSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT Agitation and aggression are common in older adults with dementia. To date, there is no FDA-approved treatment strategy available for managing these symptoms. Furthermore, treatments that are used off-label (i.e., antipsychotics) in this clinical context have significant risks associated with them. Preliminary reports suggest that electroconvulsive therapy (ECT) may be efficacious as a treatment in this context. A number of small, within-group comparison studies have reported a general improvement in agitation, aggression, and level of functioning following ECT in patients with dementia. However, several limitations limit the certainty of these conclusions, including the small sample size and lack of a control group in the studies. Furthermore, these reports do not have long-term follow-up beyond the initial index series of ECT (only 3-5 weeks). The proposed supplement study will fill these gaps in knowledge by conducting a propensity-score matched observational cohort of respectable sample size (N~1000 per group) and duration (1-2 years) using nationally representative Medicare claims data. This application is in response to NOT-AG-20-008, which calls for supplemental projects to “expand existing awards not currently focused on Alzheimer’s disease and its related dementias (AD/ADRD)” which will lead to subsequent independent research projects. This project will aim to 1) examine the association of ECT use with long-term disruptive behavioral symptoms (e.g., aggression and agitation); and 2) evaluate the association of ECT use with long-term cognitive and physical functional outcomes among older adults with co-morbid depression and dementia. We will compare outcomes over time across those who receive ECT and those who do not (non-ECT group). The outcomes of interest come from the OASIS survey, a comprehensive quarterly assessment of dementia patients in nursing homes. This survey contains detailed data on behavioral, cognitive, and functional outcomes. Data will be drawn from Medicare data of 650,000 beneficiaries aged 65 or older that is already in- house for the parent grant. Given this existing database, our preliminary data queries suggest we will have sufficient data for a longitudinal study of 2,000 patients. We will use a propensity-score matched cohort to identify a group of patients who do not receive ECT who are otherwise comparable to those who do. A mixed- model analysis will be utilized to examine outcomes over time. Our hypothesis is that ECT is associated with better outcomes compared to the non-ECT group. Our focus on comorbid depression/dementia is out of convenience given the dataset that exists in-house and the limitations of the supplement notice that the work must be completed in one year. Promising findings from this study would provide preliminary data to undertake a larger, independent study of this association in a more representative sample of individuals with dementia without depression, making anticipated findings more generalizable and relevant to practice.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10264145
  • 项目类别:
  • 资助金额:
    $57.55万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10472036
  • 项目类别:
  • 资助金额:
    $96.9万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10115267
  • 项目类别:
  • 资助金额:
    $60.22万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10688291
  • 项目类别:
  • 资助金额:
    $96.6万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
海外基金